Bendamustine in the treatment of B-cell non-Hodgkin lymphoma


Bendamustine is a uniquely structuredalkylating agent that lacks cross-resistance with other alkylators. This agent has a high degreeof activity against a variety of tumor cell lines.Based on clinical data from randomized phase III trials, bendamustine, with or without rituximab, hasbeen shown to be an appropriate option for first-line treatment or treatment of relapsed/refractory patients with indolent non-Hodgkin’s lymphoma or elderly patients with mantle cell lymphoma. Bendamustine treatment is associated with abetter therapeutic index and offers an improved overall quality of life compared to R-CHOP or R-CVP. It is now often used as achemotherapy backbone for combination with novel drugs including ibrutinib or idelalisib. This article provides a comprehensivesummaryof the clinical data along with practical adviceonhowto optimallymanagepatients with bendamustine therapy, includingdose recommendations, antiemetic prophylaxis, prevention of infusion and skin reactions, as well as prophylaxis of opportunisticinfections. This information might be helpful for clinicians using bendamustine in their daily practice.

Full Text

Restricted Access

About the authors

L G Babicheva

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

I V Poddubnaya

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1


  1. Press O.W. Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol 2013; 31: 1496-8.
  2. National Comprehensive Cancer Network. NCCN guidelines lymphoma, version 1.2013. Available at http: //
  3. Friedberg J.W, Taylor M.D, Cerhan J.R et al. Follicular lymphoma in the United States: First report of the national Lympho Care study. J Clin Oncol 2009; 27: 1202-8.
  4. Morschhauser F, Seymour J.F, Feugier P et al. Impactof induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 2011; 22 (Suppl. 4): 89.
  5. Rummel M.J, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treament for patients with indolent and mantle-cell lymphomas: Anopen-label, multicentre, randomised, phase 3non-inferiority trial. Lancet 2013; 381: 1203-10.
  6. Flinn I.W, van der Jagt R.H, Kahl B.S et al. Anopen-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) infirst-line treatment of patients with advanced indolentnon-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study. Paper presented at: ASH 2012; Atlanta, GA.
  7. Witzig T.E, Vukov A.M, Habermann T.M et al., Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23 (6): 1103-8.
  8. Friedberg J.W, Vose J.M, Kelly J.L et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807-12.
  9. Merryman R, Edwin N, Redd R et al. Rituximab/Bendamustin and Rituximab/Cytarabine (RB/RC) induction chemotherapy for transplant-eligible patients with mantle-cell lymphoma: A pooled analysis of two phase 2 clinical trials and off-trial experience. American Society of Hematology Annual Conference 2018.
  10. Поддубная И.В., Бабичева Л.Г. и др. Результаты проспективной многоцентровой наблюдательной программы BENEFIT: оценка рутинного применения комбинированной терапии бендамустином и ритуксимабом с последующей поддерживающей терапией ритуксимабом у пациентов с рецидивами или рефрактерными индолентными В-клеточными лимфомами (иНХЛ). Практическая онкология. 2017; 18 (14): 376-88. [ Poddubnaia I.V., Babicheva L.G. i dr. Rezul'taty prospektivnoi mnogotsentrovoi nabliudatel'noi programmy BENEFIT: otsenka rutinnogo primeneniia kombinirovannoi terapii bendamustinom i rituksimabom s posleduiushchei podderzhivaiushchei terapiei rituksimabom u patsientov s retsidivami ili refrakternymi indolentnymi V-kletochnymi limfomami (iNKhL). Prakticheskaia onkologiia. 2017; 18 (14): 376-88.]
  11. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97 (1): 101-6.
  12. Kahl B.S, Bartlett N.L, Leonard J.P et al. Bendamustineis effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study. Cancer 2010; 116: 106-14.
  13. Martinelli G, Schmitz S.F, Utiger U et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28 (29): 4480-4.
  14. Taverna C, Martinelli G, Hitz F et al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2016; 34 (5): 495-500.
  15. Knauf W.U, Lissichkov T, Aldaoud A et al. PhaseIII randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-84.
  16. Marcus R.E, Davies A.J, Ando K et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomised Phase III GALLIUM study. Abstract 6. 58th Annual American Society of Hematology Meeting, 3-6 December, 2016.
  17. Kahl B.S, Bartlett N.L, Leonard J.P et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116 (1): 106-14.
  18. Dewilde S, Woods B et al. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. J Med Economics 2014; 17 (2): 111-24, 1941-837X.
  19. Visco C, Finotto S, Zambello R et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma in eligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442-9.
  20. Sehn L.H, Chua N, Mayer J et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081-93.
  21. Fowler N, Kahl B.S, Lee P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 2011; 29: 3389-95.
  22. Fowler N, DeVos S, Schreeder M. Combinations of the phosphatidylinositol 3-kinase-delta (PI3Kd) inhibitor GS1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent Non-Hodgkin lymphoma: Results from a phase I study. Paper presented at: ASH 2012; December 10, 2012; Atlanta, GA.
  23. Blum K.A, Christian B, Flynn J.M et al. A phase Itrial of the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).Paper presented at: ASH 2012; December 8, 2012; Atlanta, GA.
  24. Rummel M.J, Al-Batran S.E, Kim S.Z et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 3383-9.
  25. Cheson B.D, Wendtner C.M, Pieper A et al. Optimaluse of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from aninternational consensus panel. Review Clin Lymphoma Myeloma Leuk 2010; 10: 21-7.
  26. Caimi P.F, Barr P.M, Berger N.A et al. Non-Hodgkin’s lymphoma in the elderly. Drugs Aging 2010; 27: 211-38.
  27. Preiss R, Teichert J, Poеnisch W et al. Pharmacokinetic sand toxicity profile of bendamustine in myeloma patients with end-stage renal disease. Hematol J 2003; 4 (Suppl. 1): abstract 394.
  28. Alamdari H.S, Pinter-Brown L, Cassarino D.S et al. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 2010; 16: 1.
  29. Cephalon. Treanda: Highlights of prescribing information. 022303lbl
  30. Glance L.E, Cumpston A, Kanate A et al. Bendamustine-associated hemolytic anemia. Ann Pharmacother2009; 11: 1903-6.
  31. Tombleson R.L, Ho V, Sokol L et al. Optimizing premedications in the prevention of bendamustine in fusion-related reactions. Cancer Control 2012; 3: 245-7.
  32. Carter S.J, Bernstein S.H, Friedberg J.W et al. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res 2011; 35: e223-224.
  33. Tsutsumi Y, Ogasawara R, Miyashita N et al. HBV reactivation in malignant lymphoma patient streated with rituximab and bendamustine. Int J Hematol 2012; 95: 588-91.
  34. Lim S.H, Pathapati S, Langevin J et al. SevereCMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2011; 91: 643-4.
  35. Schöffski P, Seeland G, Engel H et al. Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000; 11: 729-34.
  36. Friedberg J.W, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: Results from a phase II multicenter, single agent study. J Clin Oncol 2008; 10: 26: 204-10.
  37. Cheson B.D, Friedberg J.W, Kahl B.S et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 452-7.
  38. Burke J.M, van der Jagt R.H.C et al. Differences in Quality of Life between Bendamustine-Rituximab and R-CHOP/R-CVP in patients with previously untreated advanced indolent non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leukaemia 2016; 16 (4): 182-90.
  39. Owen J.S, Melhem M, Passarell J.A et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 2010; 66: 1039-49.
  40. Weide R, Feiten S, Friesenhahn V et al. Retreatmentwith bendamustine-containing regimens inpatients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphoma sachieves high response rates and some long lasting remissions. Leuk Lymphoma 2012 [Epub ahead ofprint].
  41. Burchardt C.A, Brugger W, Maschmeyer G et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R Vs. CHOP-R (NHL 1-2003 trial) of theStiL (Study group indolent Lymphomas, Germany). Blood 2009; 114: abstract 2679. Presented at ASH annual meeting, 2009.
  42. Rummel M.J, Lerchenmuеller C, Greil R et al. Bendamustine-rituximab induction followed byobservation or rituximab maintenance for newly diagnosed patients with Waldenstroеm’s macroglobulinemia: Results from a prospective, randomized, multicenter study (StiL NHL 7-2008 - MAINTAIN; identifier: NCT00877214. Paper presented at: ASH 2012; December 9, 2012; Atlanta, GA.
  43. Visani G, Malerba L, Stefani P.M et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safeand effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419-25.
  44. Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30: 3209-16.
  45. Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocyticleukemia: Amulticenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-66.
  46. Federico M, Caballero B, Marcheselli L et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol 2018; 5 (8): e359-e367. doi: 10.1016/S2352-3026 (18)30090-5



Abstract - 11

PDF (Russian) - 1





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies